Unity Biotechnology Future Growth
Future criteria checks 3/6
Unity Biotechnology is forecast to grow earnings and revenue by 55.2% and 68.3% per annum respectively. EPS is expected to grow by 54.3% per annum. Return on equity is forecast to be -61.6% in 3 years.
Key information
55.2%
Earnings growth rate
54.3%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 68.3% |
Future return on equity | -61.6% |
Analyst coverage | Low |
Last updated | 26 Nov 2024 |
Recent future growth updates
Recent updates
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?
Nov 05Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?
Jul 12Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation
Mar 05Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
Nov 18UNITY Biotechnology falls 7% on reverse stock split
Oct 19Unity Biotechnology cuts stock sales agreement in half to $25M
Aug 19Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M
Aug 12A Look At Unity's UBX1325 Phase 1 Results
Jul 26Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently
Dec 22A Look Inside Unity Bio's Transition To An Ophthalmology Company
Nov 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 26 | -13 | N/A | N/A | 2 |
12/31/2025 | N/A | -32 | N/A | N/A | 2 |
12/31/2024 | N/A | -25 | N/A | N/A | 2 |
9/30/2024 | N/A | -22 | -23 | -23 | N/A |
6/30/2024 | N/A | -30 | -24 | -24 | N/A |
3/31/2024 | N/A | -40 | -31 | -31 | N/A |
12/31/2023 | N/A | -40 | -37 | -37 | N/A |
9/30/2023 | N/A | -34 | -41 | -41 | N/A |
6/30/2023 | N/A | -33 | -45 | -45 | N/A |
3/31/2023 | 0 | -31 | -49 | -49 | N/A |
12/31/2022 | 0 | -44 | -53 | -52 | N/A |
9/30/2022 | 5 | -56 | -46 | -46 | N/A |
6/30/2022 | 5 | -59 | -47 | -46 | N/A |
3/31/2022 | 5 | -64 | -45 | -45 | N/A |
12/31/2021 | 5 | -61 | -45 | -45 | N/A |
9/30/2021 | N/A | -70 | -57 | -57 | N/A |
6/30/2021 | N/A | -81 | -63 | -62 | N/A |
3/31/2021 | N/A | -82 | -69 | -68 | N/A |
12/31/2020 | N/A | -94 | -79 | -78 | N/A |
9/30/2020 | N/A | -92 | -78 | -77 | N/A |
6/30/2020 | N/A | -86 | -78 | -77 | N/A |
3/31/2020 | N/A | -91 | -78 | -77 | N/A |
12/31/2019 | N/A | -82 | -74 | -72 | N/A |
9/30/2019 | N/A | -86 | -71 | -70 | N/A |
6/30/2019 | N/A | -83 | -68 | -67 | N/A |
3/31/2019 | N/A | -79 | -67 | -65 | N/A |
12/31/2018 | N/A | -76 | -58 | -57 | N/A |
9/30/2018 | 1 | -67 | -57 | -55 | N/A |
6/30/2018 | 1 | -60 | N/A | -51 | N/A |
3/31/2018 | 1 | -52 | N/A | -42 | N/A |
12/31/2017 | 1 | -45 | N/A | -38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UBX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: UBX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: UBX is expected to become profitable in the next 3 years.
Revenue vs Market: UBX is forecast to have no revenue next year.
High Growth Revenue: UBX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UBX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 00:09 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Unity Biotechnology, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Elemer Piros | Cantor Fitzgerald & Co. |
Yigal Nochomovitz | Citigroup Inc |
Andrew Fein | H.C. Wainwright & Co. |